Investment & Partnering
ARAIM is a privately held clinical stage pharmaceutical company developing treatments for Neurology and Diabetes related disorders through a proprietary novel platform technology. ARAIMs lead asset, Cibinetide, is in Phase 2 to delay disease progression and manage pain associated with Diabetic Neuropathy and Neuropathy associated with Sarcoidosis.
ARAIM has benefitted from collaborating with leading academic researchers from renowned research institutions in developing the scientific foundations for our platform. As we progress towards the patient, we are actively seeking collaboration from academic researchers, biopharmaceutical companies, and investors
For investment considerations please contact Investors@araimpharma.com
For partnering considerations please contact PharmaPartners@araimpharma.com
For research considerations please contact Research@araimpharma.com